PIL
20/01/2015 09:17
GENERAL
NOT PRICE SENSITIVE
REL: 0917 HRS Promisia Integrative Limited
GENERAL: PIL: Publication of Peer-Reviewed Research Paper on Arthrem(TM)
Publication of Peer-Reviewed Research Paper on Arthrem(TM)
Mr Malcolm Johnson, Chairman of Promisia Integrative Limited announced today
the publication of a peer-reviewed scientific research paper. The paper's
first author is the company's Principal Scientist Dr Sheena Hunt. The
research paper was published by the Journal of Inflammation Research, a
recognised and authoritative international journal.
The published results show that the primary ingredient of Arthrem(TM),
Promisia's proprietary plant extract, has potent anti-inflammatory activity
in vitro. Concentrations as low as 0.05% completely inhibited production of
the inflammatory mediator tumour necrosis factor-alpha. The extract was also
a strong inhibitor of the cyclooxygenase (COX) inflammatory marker,
prostaglandin E2.
Commenting on the research paper, the Company's Principal Scientist Dr Sheena
Hunt said: "The authors were delighted that our paper was accepted for
publication in a reputable peer-reviewed journal. This will enhance the
credibility of our product within the scientific community".
The Company's Chief Executive Officer Mr Charles Daily said: "The studies
were conducted by independent laboratory Trinity Bioactives in Wellington."
Mr Daily added: "This publication is a prime example of the type of robust
scientific research that is needed in this industry".
The paper can be accessed via this url:
http://www.dovepress.com/articles.php?article_id=19981
For further information please contact:
Mr. Charles Daily, Chief Executive Officer on (04) 894 8524 or
Mr. Malcolm Johnson, Chairman on (04) 479 3377
ENDS
End CA:00259881 For:PIL Type:GENERAL Time:2015-01-20 09:17:02
